Gyula Poór

Gyula Poór

Auto-generated profile, based on publicly available information

Gyula Poór

Department of Rheumatology, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2022 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
ÁHÁron Hölgyesi
Áron Hölgyesi
GPGyula Poór
Gyula Poór
Petra BajiPetra Baji
Petra Baji
Zsombor ZrubkaZsombor Zrubka
Zsombor Zrubka
MFMiklós Farkas
Miklós Farkas
MPMárta Péntek
Márta Péntek
Background: The Versus Arthritis Musculoskeletal Health Questionnaire (MSK-HQ) measures symptom severity and health-related quality of life (HRQoL) of people with musculoskeletal (MSK) conditions. We aimed to test the psychometric properties of the MSK-HQ among the general adult population and identify the determinants of MSK-HQ states. In addition, we aimed to explore the relationship between MSK-HQ and standard well-being measurement tools. Methods: The translation proccess of the MSK-HQ into Hungarian followed the standard methods provided by the developer. A cross-sectional online survey was performed in Hungary involving a population normative sample (N = 2004, women: 53.1%; mean age: 48.3, SD = 16.6 years). Socio-demographic characteristics and self-reported MSK disorders were recorded. Alongside the MSK-HQ, standard measures of HRQoL (EQ-5D-5L), physical functioning (HAQ-DI) and well-being (ICECAP-A/O, WHO-5, Happiness VAS) were applied. Clinical and convergent validity were assessed by subgroup comparisons (Mann–Whitney-U and Kruskal–Wallis tests) and Spearman’s rank correlations. Internal consistency was assessed by Cronbach’s alpha. Test–retest reliability (N = 50) was evaluated by intraclass correlation coefficient (ICC). Predictors of MSK-HQ were analysed by ordinary least square multiple regressions. Results: The mean MSK-HQ index score was 44.1 (SD = 9.9). MSK-HQ scores were significantly lower in subgroups with self-reported MSK disorders. Correlations were strong between MSK-HQ and EQ-5D-5L (0.788), EQ VAS (0.644) and HAQ-DI (-0.698) and moderate with the well-being measures (p < 0.05). Cronbach’s alpha was 0.924 and ICC was 0.936 (p < 0.05). Being a man, living in the capital, having higher income and education were positively associated with MSK-HQ scores. Conclusions: This is the first study to prove the validity and reliability of the MSK-HQ among the general public. The impact of socio-demographic characteristics on MSK-HQ scores deserves consideration in clinical studies.

1 January 2016 in Orvosi Hetilap
Verified
Journal Article
Open access
ZSZsuzsa Schmidt
Zsuzsa Schmidt
GPGyula Poór
Gyula Poór
Absztrakt A polymyalgia rheumatica az 50 év feletti korosztály gyulladásos mozgásszervi megbetegedése, amelyet a vállak, csípők, nyak kifejezett fájdalma, reggeli merevsége és nagy szisztémás gyulladás jellemez, rendszerint jól és gyorsan reagál kis dózisú glükokortikoidra. Óriássejtes arteritissel való társulása régóta ismert. Az utóbbi évek klinikai megfigyelései és tudományos eredményei újabb kihívásokat állítottak a reumatológusszakma elé. Az aspecifikus, de jellegzetes polymyalgiás szindróma mellett változatos perifériás ízületi tüneteket figyeltek meg. A mozgásszervi tünetek hátterében mágneses rezonanciás és ultrahangvizsgálatokkal enyhe, múló, eróziót nem okozó synovitist igazoltak, amely döntően extraartikuláris megjelenésű. Mivel potognosztikus tünete nincs, a PMR diagnózisa továbbra is a differenciáldiagnosztikailag szóba jövő betegségektől való elkülönítésen alapul. Különösen nehéz az időskori gyulladásos arthritisek, időskori rheumatoid arthritis, késői kezdetű spondylarthritis elkülönítése. 2012-ben az amerikai (ACR) és az európai (EULAR) reumatársaságok polymyalgia rheumatica munkacsoportja klasszifikációs kritériumokat hozott létre, amelynek pontozásos algoritmusa szintén a klinikai tünetekre épül, az ultrahang-kritériumok további segítséget jelentenek. A polymyalgia rheumatica terápiája változatlanul a kis dózisú glükokortikoid, azt helyettesítő hatásos gyógyszer ez ideig nem ismert. A glükokortikoidterápia általában 1–1,5 éven belül elhagyható, az esetek egy részében azonban relapsusokkal járó krónikus lefolyás figyelhető meg, a glükokortikoidok hosszú távú, éveken át tartó adása szükséges. A glükokortikoidok jól ismert mellékhatásai (diabetes, hypertonia, hyperlipidaemia, osteoporosis) jelentős morbiditást, gazdasági terhet jelentenek. Újabb gyógyszervizsgálatok folyamatban vannak. A betegség korai felismerése, a glükokortikoidterápia mielőbbi elkezdése és szabályos kivitelezése, a mellékhatások megelőzése és kezelése a reumatológusok mellett a családorvosok napi feladata. A polymyalgia rheumatica ismerete az összes orvosi szakma számára nélkülözhetetlen. Orv. Hetil., 2016, 157(1), 2–12. Abstract Polymyalgia rheumatica is an inflammatory musculoskeletal disorder of people aged 50 years or over, characterised by pain, aching and morning stiffness in the shoulder girdle and often hip girdle and neck. Marked systemic inflammation and rapid response to corticosteroid therapy are characteristic features. Giant cell arteritis is a well-known association of polymyalgia rheumatica. Recent clinical evidence and scientific results in the field have provided new challenges for rheumatologists. Besides the aspecific – although characteristic – proximal syndrome, less well recognizable and more variable distal musculoskeletal manifestations were observed. Magnetic resonance and ultrasound studies showed mild, remitting and non-erosive synovitis, with dominating inflammation of the extraarticular synovial structures. As no pathognostic sign is known, the diagnosis of polymyalgia rheumatica is based on its differential diagnosis, differentiation from the polymyalgia mimics; particularly from elderly onset inflammatory arthritides, such as elderly onset rheumatoid arthritis and late onset seronegative spondylarthritis. In 2012 the international polymyalgia rheumatica work group under the guidance of the American College of Rheumatology and European League Against Rheumatism elaborated new classification criteria, the scoring algorythm of which is based on clinical symptoms, with ultrasonography increasing the specificity. Corticosteroids remain the cornerstone of the therapy of polymyalgia rheumatica. No effective steroid-sparing drug has been found to date. Corticosteroids are generally needed for 1–1.5 years, though some patients have a chronic-relapsing course and require corticosteroids for several years. Well known corticosteroid-related side effects (diabetes, hypertension, hyperlipidaemia and osteoporosis) cause significant morbidity and economic burden on the society. Novel therapeautic approaches are on trial. Early recognition of the disease, early start of corticosteroids and a well-defined course, prevention and management of side effects are everyday tasks for rheumatologists and family doctors. Knowledge of polymyalgia rheumatica is essential for all medical specialties. Orv. Hetil., 2016, 157(1), 2–12.

27 July 2022 in OBM Geriatrics
Verified
Journal Article
Open access
PDF file
ZSZsuzsanna M. Schmidt
Zsuzsanna M. Schmidt
GPGyula Poor
Gyula Poor
MDMember Hung Acad Sci Poor Dsc
Member Hung Acad Sci Poor Dsc
Polymyalgia rheumatica (PMR) is an age-related chronic inflammatory disease with rheumatic features at the fore. In addition to the high-grade systemic inflammation, it is characterized by typical "polymyalgic" musculoskeletal symptoms, including diffuse and severe pain and prolonged morning stiffness of the shoulder girdle, pelvic girdle, and neck. PMR is a member of the so-called giant cell arteritis complex; however, in spite of the marked systemic inflammation in PMR, the local vasculitis process aborts. The pathological background is synovitis, with a predominant inflammation of the extra-articular synovial structures. Synovitis of PMR is mild, transient, and non-erosive. Distal musculoskeletal symptoms are also observed but are more variable and less recognizable than the predominant proximal polymyalgic syndrome. PMR often overlaps with elderly-onset seronegative arthritides, elderly-onset rheumatoid arthritis, late-onset seronegative spondylarthritis, and the RS3PE1 syndrome. Although glucocorticoids are the cornerstone of PMR therapy, considerable hope is attached to tocilizumab, an IL-6 receptor inhibitor.